Clinical trials in chronic diseases

Area of Science:

• Clinical Trials Methodology
• Biostatistics
• Evidence-Based Medicine

Background:

• Crossover and parallel group designs are common clinical trial methodologies.
• Despite early negative publicity, crossover designs were frequently published in the 1980s.
• Understanding design strengths and weaknesses is crucial for clinical decision-making.

Purpose of the Study:

• To provide an overview of the advantages and disadvantages of crossover and parallel group clinical trial designs.
• To highlight the suitability of crossover designs for specific therapeutic areas.
• To inform clinical practitioners about the implications of trial design choices.

Main Methods:

• Analysis of published crossover/self-controlled clinical trials from the early 1980s.
• Comparative assessment of strengths and weaknesses between crossover and parallel group designs.
• Evaluation of design applicability across different phases and types of studies (e.g., symptomatic vs. curative).

Main Results:

• Crossover designs offer benefits such as eliminating between-subject variability, requiring smaller sample sizes, posing fewer ethical concerns, and allowing subject preference expression.
• Key weaknesses of crossover designs include potential carryover effects between treatment periods and time effects from evolving symptoms.
• Crossover designs are most appropriate for symptomatic treatments of stable diseases, particularly in chronic conditions, and less suitable for phase III/IV studies of rapidly evolving conditions.

Conclusions:

• Crossover designs present significant advantages for specific clinical trial applications, especially in managing stable, symptomatic diseases.
• Awareness of crossover design limitations, such as carryover and time effects, is essential for accurate interpretation of results.
• The choice of clinical trial design significantly impacts the validity and applicability of findings, particularly for evidence-based practice.